{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:31:39Z","timestamp":1789180299348,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00228-026-04075-x","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:13:45Z","timestamp":1778120025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy and safety of pentoxifylline in the treatment of chronic kidney disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Yanfang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feijie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"3","key":"4075_CR1","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/s2214-109x(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK, Okpechi IG, Levin A, Ye F, Damster S, Arruebo S et al (2024) An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health 12(3):e382\u2013e95. https:\/\/doi.org\/10.1016\/s2214-109x(23)00570-3","journal-title":"Lancet Glob Health"},{"issue":"4","key":"4075_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","volume":"139","author":"TH Jafar","year":"2003","unstructured":"Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE et al (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139(4):244\u2013252. https:\/\/doi.org\/10.7326\/0003-4819-139-4-200308190-00006","journal-title":"Ann Intern Med"},{"issue":"2","key":"4075_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T et al (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42(2):152\u2013161. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736","journal-title":"Eur Heart J"},{"issue":"10","key":"4075_CR4","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/asn.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. J Am Soc Nephrol 23(10):1631\u20131634. https:\/\/doi.org\/10.1681\/asn.2011111078","journal-title":"J Am Soc Nephrol"},{"key":"4075_CR5","doi-asserted-by":"publisher","unstructured":"Pastrana DV (2020) mSphere of Influence: it\u2019s not me, it\u2019s you-how donor factors influence kidney transplant outcomes. mSphere 5(1). https:\/\/doi.org\/10.1128\/mSphere.00964-19","DOI":"10.1128\/mSphere.00964-19"},{"issue":"19","key":"4075_CR6","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.13748\/j.cnki.issn1007-7693.2020.19.005","volume":"37","author":"JX Yan","year":"2020","unstructured":"Yan JX, Zhan SJ, Tan H (2020) Effect of Pentoxifylline Combined with Bone Marrow Mesenchymal Stem Cells on Inflammatory Factors and NF-\u03baB Signaling Pathways in Glomerular Mesangial Cells Induced by High Glucose. Chin J Mod Appl Pharm 37(19):2328\u20132332. https:\/\/doi.org\/10.13748\/j.cnki.issn1007-7693.2020.19.005","journal-title":"Chin J Mod Appl Pharm"},{"issue":"6","key":"4075_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.medcli.2024.09.032","volume":"164","author":"H Zakaria","year":"2025","unstructured":"Zakaria H, Hamdy NA, Sayed-Ahmed NAH, El-Mallah A (2025) Effect of pentoxifylline on hepcidin and iron profile in hemodialysis patients: A randomized, double-blind, placebo-controlled clinical trial. Med Clin (Barc) 164(6):263\u2013270. https:\/\/doi.org\/10.1016\/j.medcli.2024.09.032","journal-title":"Med Clin (Barc)"},{"issue":"3","key":"4075_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1440-1797.2009.01203.x","volume":"15","author":"P Ferrari","year":"2010","unstructured":"Ferrari P, Mallon D, Trinder D, Olynyk JK (2010) Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrol (Carlton) 15(3):344\u2013349. https:\/\/doi.org\/10.1111\/j.1440-1797.2009.01203.x","journal-title":"Nephrol (Carlton)"},{"issue":"8","key":"4075_CR9","doi-asserted-by":"publisher","first-page":"e0134104","DOI":"10.1371\/journal.pone.0134104","volume":"10","author":"D Bolignano","year":"2015","unstructured":"Bolignano D, D\u2019Arrigo G, Pisano A, Coppolino G (2015) Pentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. PLoS ONE 10(8):e0134104. https:\/\/doi.org\/10.1371\/journal.pone.0134104","journal-title":"PLoS ONE"},{"issue":"1","key":"4075_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12882-025-04399-3","volume":"26","author":"ARM Galal","year":"2025","unstructured":"Galal ARM, Teama NM, Abu-Elfotuha K, Alatawi AD, Alshareef H, Hamdan AME et al (2025) The potential adding therapeutic effect of pentoxifylline and\/or folic acid for chronic kidney disease patients: randomized controlled trial. BMC Nephrol 26(1):468. https:\/\/doi.org\/10.1186\/s12882-025-04399-3","journal-title":"BMC Nephrol"},{"key":"4075_CR11","unstructured":"National Institute for Health and Care Research. PROSPERO home page National Institute for Health and Care Research. Available from: https:\/\/www.crd.york.ac.uk\/PROSPERO\/"},{"key":"4075_CR12","unstructured":"National Heart L, and Blood Institute. Study quality assessment tools: National Heart, Lung, Blood Institute. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"issue":"3","key":"4075_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.34172\/ps.2024.3","volume":"30","author":"L Rezadoost","year":"2024","unstructured":"Rezadoost L, Khosroshahi HT, Farnood F, Sarbakhsh P, Behzad H, Gharakhani A (2024) Effects of Pentoxifylline on Inflammatory Factors and Quality of Life in Maintenance Hemodialysis Patients. Pharm Sci 30(3):304\u2013311. https:\/\/doi.org\/10.34172\/ps.2024.3","journal-title":"Pharm Sci"},{"issue":"6","key":"4075_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.5455\/njppp.2022.12.04159202221042022","volume":"12","author":"R Thottol","year":"2022","unstructured":"Thottol R, George A (2022) Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. Natl J Physiol Pharm Pharmacol 12(6):823\u2013827. https:\/\/doi.org\/10.5455\/njppp.2022.12.04159202221042022","journal-title":"Natl J Physiol Pharm Pharmacol"},{"issue":"6","key":"4075_CR15","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.13040\/IJPSR.0975-8232.9","volume":"9","author":"A Alidadi","year":"2018","unstructured":"Alidadi A, Fard R (2018) Effect of pentoxifylline on serum CRP levels in hemodialysis patients compared with placebo. Int J Pharm Sci Res 9(6):2347\u20132350. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.9","journal-title":"Int J Pharm Sci Res"},{"issue":"5","key":"4075_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.amjms.2017.12.015","volume":"355","author":"S Rabizadeh","year":"2018","unstructured":"Rabizadeh S, Dehghani Firouzabadi F, Noshad S, Esteghamati S, Afarideh M, Ghajar A et al (2018) Beneficial Effects of Pentoxifylline Plus Losartan Dual Therapy in Type 2 Diabetes with Nephropathy. Am J Med Sci 355(5):442\u2013448. https:\/\/doi.org\/10.1016\/j.amjms.2017.12.015","journal-title":"Am J Med Sci"},{"issue":"1","key":"4075_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.15171\/jrip.2017.11","volume":"6","author":"H Shahbazian","year":"2017","unstructured":"Shahbazian H, Ghorbani A, Zafar-Mohtashami A, Balali A, AleAli A, Lashkarara GR (2017) Administration of pentoxifylline to improve anemia of hemodialysis patients. J Ren Inj Prev 6(1):61\u201364. https:\/\/doi.org\/10.15171\/jrip.2017.11","journal-title":"J Ren Inj Prev"},{"issue":"1","key":"4075_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1179\/1351000215y.0000000022","volume":"21","author":"L Zhang","year":"2016","unstructured":"Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A et al (2016) The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Rep 21(1):14\u201323. https:\/\/doi.org\/10.1179\/1351000215y.0000000022","journal-title":"Redox Rep"},{"issue":"7","key":"4075_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5301\/ijao.5000340","volume":"37","author":"SA Antunes","year":"2014","unstructured":"Antunes SA, Vilela RQ, Vaz JD, Canziani ME (2014) Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis. Int J Artif Organs 37(7):521\u2013528. https:\/\/doi.org\/10.5301\/ijao.5000340","journal-title":"Int J Artif Organs"},{"issue":"4","key":"4075_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3265\/Nefrologia.pre2013.Apr.11654","volume":"33","author":"JM Mora-Guti\u00e9rrez","year":"2013","unstructured":"Mora-Guti\u00e9rrez JM, Ferrer-Nadal A, Garc\u00eda-Fern\u00e1ndez N (2013) Effect of pentoxifylline on anaemia control in haemodialysis patients: retrospective observational case-control study. Nefrologia 33(4):524\u2013531. https:\/\/doi.org\/10.3265\/Nefrologia.pre2013.Apr.11654","journal-title":"Nefrologia"},{"issue":"4","key":"4075_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s13539-013-0115-9","volume":"4","author":"M Rattanasompattikul","year":"2013","unstructured":"Rattanasompattikul M, Molnar MZ, Lee ML, Dukkipati R, Bross R, Jing J et al (2013) Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial. J Cachexia Sarcopenia Muscle 4(4):247\u2013257. https:\/\/doi.org\/10.1007\/s13539-013-0115-9","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"4075_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.5301\/jn.5000077","volume":"25","author":"M Goicoechea","year":"2012","unstructured":"Goicoechea M, Garc\u00eda de Vinuesa S, Quiroga B, Verdalles U, Barraca D, Yuste C et al (2012) Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol 25(6):969\u2013975. https:\/\/doi.org\/10.5301\/jn.5000077","journal-title":"J Nephrol"},{"issue":"2","key":"4075_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5455\/medarh.2012.66.84-86","volume":"66","author":"M Mortazavi","year":"2012","unstructured":"Mortazavi M, Seyrafian S, Taheri S, Nasiri R, Dolatkhah S, Naini AE et al (2012) Role of pentoxifylline in treatment of anemic patients suffering chronic hemodialysis: a randomized clinical trial. Med Arh 66(2):84\u201386. https:\/\/doi.org\/10.5455\/medarh.2012.66.84-86","journal-title":"Med Arh"},{"issue":"5","key":"4075_CR24","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/ndt\/gfr579","volume":"27","author":"L Gonz\u00e1lez-Espinoza","year":"2012","unstructured":"Gonz\u00e1lez-Espinoza L, Rojas-Campos E, Medina-P\u00e9rez M, Pe\u00f1a-Quintero P, G\u00f3mez-Navarro B, Cueto-Manzano AM (2012) Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol Dial Transpl 27(5):2023\u20132028. https:\/\/doi.org\/10.1093\/ndt\/gfr579","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4075_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3109\/08860221003602645","volume":"32","author":"J Roozbeh","year":"2010","unstructured":"Roozbeh J, Banihashemi MA, Ghezlou M, Afshariani R, Salari S, Moini M et al (2010) Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. Ren Fail 32(2):172\u2013178. https:\/\/doi.org\/10.3109\/08860221003602645","journal-title":"Ren Fail"},{"issue":"4","key":"4075_CR26","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1053\/j.ajkd.2008.11.026","volume":"53","author":"RM Perkins","year":"2009","unstructured":"Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM (2009) Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 53(4):606\u2013616. https:\/\/doi.org\/10.1053\/j.ajkd.2008.11.026","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"4075_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/j.ajkd.2008.05.012","volume":"52","author":"SL Lin","year":"2008","unstructured":"Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ (2008) Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis 52(3):464\u2013474. https:\/\/doi.org\/10.1053\/j.ajkd.2008.05.012","journal-title":"Am J Kidney Dis"},{"key":"4075_CR28","doi-asserted-by":"publisher","unstructured":"Mej\u00eda-Rodr\u00edguez O, \u00c1vila-D\u00edaz M, Prado-Uribe C, Galv\u00e1n-Plata ME, Vega G\u00f3mez H, \u00c1lvarez-Aguilar C et al (2026) Short- and middle-term nephroprotective and cardioprotective effects of pentoxifylline in patients with diabetic nephropathy: a randomized controlled trial. Med Sci (Basel) 14(1). https:\/\/doi.org\/10.3390\/medsci14010026","DOI":"10.3390\/medsci14010026"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04075-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:17:43Z","timestamp":1781072263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04075-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4075"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04075-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinic trial number"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}